Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa

Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa

308425

Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa

A Phase 1 trial of AP-472, Appello Pharmaceutical‘s lead investigational therapy to ease levodopa-induced dyskinesia in Parkinson’s disease, has started dosing healthy adults. The study will randomly assign young, middle-aged, and elderly adults to escalating doses of AP-472 or a placebo. It aims to evaluate the therapy’s safety, tolerability, and pharmacokinetics, which refers to the movement of a medicine into, through, and out of the body. Results will help to inform the best doses for further testing…

You must be logged in to read/download the full post.